TSHA Q3 2025 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$286,000

Operating Income

-$34M

Net Income

-$33M

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$317M

Total Liabilities

$98M

Stockholders' Equity

$219M

Cash & Equivalents

$297M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$2M	-100.0%
Gross Profit	-$286,000	$2M	-116.0%
Operating Income	-$34M	-$26M	-31.4%
Net Income	-$33M	-$26M	-28.2%